This year's most read stories from MedWatch
1. Former Novo employee alleges sexual harassment, discrimination: success meant flirting with boss
2. Following recalls and delays, Novo Nordisk kicks off smart insulin pen launch
3. Novo Nordisk has three biopharma blockbusters on the way
4. Orphazyme not seeking fresh capital despite reduced cash position
6. Novo Nordisk's new VP of digital health to focus on internal and external innovation
7. Anthony Mancini will help Genmab take its next steps
8. Novo Nordisk after US delivery issues: New obesity drug launch set for H2 next year
10. President and CEO of Leo Pharma to resign
11. Unvaccinated staff not welcome at Novo Nordisk's US HQ
12. Demant CEO on implant recall and sales halt: "This is very serious"
13. Novo Nordisk's Wegovy sells like hot cakes in the US – increases production
14. Semaglutide fails in phase II trial within fatty liver disease
15. Novo Nordisk chairman on top wages: "It's a hard balance to strike"
